N/A N=100 Mental Health Services for Prisoners With SMI
Mental Disorder
Primary: Change in Levels of Aggression Score From Baseline to Month 3 — -4.81; -2.68 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=34 Sustained Acoustic Medicine (SAM) Combined With a Diclofenac Ultrasound Coupling Patch for Knee Osteoarthritis
Osteo Arthritis Knee · Arthritis
Primary: Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline — 2.00 pain units on a scale — p=<0.001
Phase 3 N=1,861 Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19
COVID-19
Primary: Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2) — -0.20; -0.77; -0.78 Percent Change — p=<0.0001
Early Phase 1 N=11 Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study
Cortical Excitability · Psychiatric Disorder
Primary: The Change of Motor Cortex Excitability Measures by ppTMS — 0.059; 0.005; 0.073; -0.341 Ratio
N/A N=53 Same Day Subcutaneous ICD And Send Home (DASH)
Cardiomyopathies · Cardiac Death, Sudden
Primary: Rate of Successful Completion of S-ICD Implantation and Discharge of the Patient on the Same Day the Device is Implanted Using the Analgesia Protocol. — 49 Participants
N/A N=81 Racial Differences in the Natriuretic Peptide Response to Glucose Challenge
Healthy · Natriuretic Peptides · Metabolic Syndrome
Primary: Plasma MRproANP — 23 Percentage of change
Phase 4 N=103 Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Chemotherapy-induced Nausea and Vomiting
Primary: Percentage of Participants in Cycle 1 Who Experienced One or More Adverse Events (AEs) — 80.0 Percentage of Participants
Phase 4 N=35 Investigation of the Effect of the Female Urinary Microbiome on Incontinence
Overactive Bladder · Incontinence · Nocturia
Primary: Change in the Relative Abundance of Lactobacillus — 0.275 proportion of total microbes
N/A N=131 Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root
Nasal Augmentation
Primary: Mean Difference of Change in Volume (mL) at 6 Months After Baseline Versus Pre-treatment in the Nasal Dorsum/Nasal Root Between Restylane Perlane Treatment Group and…
Phase 2 N=10 A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis (NASH) · Type2 Diabetes Mellitus
Primary: Change in MRI-Proton Density Fat Fraction (MRI-PDFF) — 21.3; 14.4; -6.9 percentage fat in the liver — p=0.03125
Phase 3 N=120 Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA
Breast - Female
Primary: Post-operative Narcotic Usage — 139.3; 169.2 milligrams (mg)
Phase 3 N=352 Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Cytomegalovirus (CMV)
Primary: Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) (CMV Viremia Clearance) at End of Week 8 — 23.9…
Phase 2 N=11 Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B
Hemophilia A With Inhibitor · Hemophilia B With Inhibitor
Primary: Bleeding Episode Prevention Success — 1.4640 score on a scale
N/A N=195 Spinal Manipulation Services vs. Prescription Drug Therapy for Long-term Care
Low Back Pain
Primary: Self-reported QOL - Physical Health — 41.7; 28.8; 31.8; 32.9 units on a scale
Phase 3 N=606 Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
Pneumococcal Infections
Primary: Geometric Mean Concentration of Serotype-specific Immunoglobulin G - Schedule A: 7-11 Months — 2.47; 3.66; 2.65; 1.71 μg/mL